Amit Shah

amitshah

Amit holds a Ph.D. in Neuroscience and spends much of his time pondering about scientific problems. At the same time, he holds a deep interest in finance and in his spare time, pontificates about companies and issues in the healthcare industry. He hopes that this will bring him closer to retiring at 50 because let's face it, academic science is not a paved road to wealth!

Recent Articles by Amit Shah

Jul 8, 2014 by Amit Shah

Why Mylan Should Buy Alkermes

The recent wave of tax inversion deals creates investment opportunities for healthcare companies headquartered in countries with low corporate tax rates. Alkermes is an attractive target and a likely suitor for this company is Mylan, which has already expressed an interest in undergoing tax inversion.

Jun 24, 2014 by Amit Shah

‘Reddy’ to Consider This Generic Stock?

Dr. Reddy's is an Indian generic drug maker that is well poised for global and local growth in an environment where innovation is faltering and patent protection expiration are negatively affecting big pharma companies.

Jun 10, 2014 by Amit Shah

Can Pfizer Curb Its Appetite for Big Acquisitions?

Pfizer has insisted on pursuing an ' acquire to survive' strategy, which has stifled innovation at the company and in the case of its recent attempt to takeover AstraZeneca, has alienated shareholders. Perhaps it's time for management to find an alternate strategy for growth that focuses on innovation and consistently execute that strategy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services